Endothelial cells (ECs) lining the blood and lymphatic vessels are dependent on receptor tyrosine kinase (RTK) -mediated signaling, which leads to growth or differentiation responses in the target cells. This signaling is required for normal development and maintenance of the vascular bed as well as for angiogenic responses in pathological conditions. Vascular endothelial cells express nonendothelial lineagerestricted RTKs such as receptors for fibroblast growth factors and epidermal growth factors, but also endothelial cell-restricted RTKs (reviewed in refs 1, 2). Two major families consist of vascular endothelial growth factor receptors (VEGFRs) and the angiopoietin receptors, also called Tie (tyrosine kinase with immunoglobulin and epidermal growth factor homology domains) receptors. VEGFRs are distinguished by an extracellular domain containing seven immunoglobulin (Ig) homology domains. The VEGFR family has three members: VEGFR-1 (also known as flt-1), VEGFR-2 (KDR/flk-1), and VEGFR-3 (FLT4) (3) (4) (5) (6) (7) . In VEGFR-3, the fifth Ig homology domain of the extracellular part is proteolytically cleaved and the resulting polypeptides remain linked by two disulfide bonds (8) . The ligands binding to VEGFRs belong to the VEGF family of growth factors, which has five cellular members: VEGF, placenta growth factor (PlGF), VEGF-B, VEGF-C, VEGF-D (9 -13) , and the recently cloned viral VEGF homologue VEGF-E (14 -16) . VEGFs have specific sites of expression and show distinct binding patterns to the different VEGFRs, reflecting the complex biological signaling involved in endothelial cell functions.
Targeted deletion of genes encoding VEGFRs in mice leads to impaired development of the vasculature and embryonic death (17) (18) (19) (20) . Despite the importance of the VEGFRs in the development of blood vasculature, VEGFR-3 is unique among these receptors in that it is found almost exclusively in lymphatic endothelium in adults. The expression of VEGFR-3 starts at embryonic day (E) 8.5 of mouse development in the angioblasts of the head mesenchyme, the cardinal vein, and the allantois (21) . During development, however, the strongest VEGFR-3 mRNA expression becomes gradually restricted first to venous endothelia, and subsequently to the lymphatic vessels (22) .
Whereas blood vessel formation has been extensively 1 Correspondence: Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute, University of Helsinki, P.O.B. 21, Haartmaninkatu 3, 00014 Helsinki, Finland. E-mail: Kari.Alitalo@Helsinki.FI studied, less is known about the regulation of lymphatic vessel growth. The development of lymphatic vessels starts at E12 by centrifugal extension of vessels from venous sacs in the perimetanephric and jugular regions (20, 23) . Thereafter, lymphatic vessels extend to most tissues growing around major arteries and become particularly abundant in the mesenterium and mediastinum. VEGFR-3, the first lymphatic endothelial cellspecific RTK, was cloned as an orphan receptor from human erythroleukemia cell and placental cDNA libraries (6, 7) and the VEGFR3 gene was located to the chromosomal segment 5q33-q35 (7, 24) . Subsequently, VEGF-C and VEGF-D were found to bind to and to activate VEGFR-3 (12, 13, 25) . VEGF-C mRNA is expressed in close proximity to its receptor VEGFR-3 during mouse development (21) . Accordingly, VEGF-C is capable of inducing hyperplasia of lymphatic vessels in transgenic mice and in chick chorioallantoic membrane (26, 27) . These results suggest that VEGFR-3 plays a role in the generation of the lymphatic system. The regulatory regions of six genes sufficient to target expression of heterologous genes specifically to the endothelial cells in vivo have been described. These comprise the promoters/enhancers of the Tie1 (28 -30) , Tie2 (30, 31) , Vegfr2 (32), intercellular adhesion molecule 2 (ICAM2) (33, 34) , von Willebrand factor (vWF) (35, 36) , and vascular endothelial cadherin (VE-cadherin) (37) genes. These genes are expressed in the endothelium of blood vessels, whereas the VEGFR3 expression is relatively specific for lymphatic endothelial cells in adults except it is also expressed in some fenestrated blood endothelial cells and angiogenic blood vessels in tumors (38, 39) . It is not clear which transcription factors regulate VEGFR3 expression or what molecular mechanisms are responsible for the restriction of its expression to the lymphatic endothelium during development. Here we have cloned and analyzed the VEGFR3 gene and characterized its structure as well as the promoter region responsible for its endothelial cell-specific expression.
MATERIALS AND METHODS

Genomic organization, exon-intron sequences, and polymorphisms of the human VEGFR3
To characterize the structure of the VEGFR3, a genomic cosmid clone (24) was subcloned as EcoRI fragments (10, 9.5, 7.0, 4.3 and 3.5 kb) into the pGEM3 vector (Promega, Madison, Wis.). The genomic clones were ordered by using 2.5, 1.2, and 0.6 kb EcoRI fragments of VEGFR3 cDNA (40) as probes in Southern blotting analysis. The cosmid subclones were sequenced using primers based on the published VEGFR3 cDNA (GenBank access. no. X68203 for VEGFR-3S and S66407 for the carboxyl-terminal tail of VEGFR-3L) (40) . The sequence data from the cosmid clone was independently confirmed by using cDNA primers from the ends of exons to amplify segments of genomic DNA. We sequenced ϳ 80% of the genomic DNA using PCR amplimers, cycle sequencing with dRhodamine ready reactions dye Terminator kit, and running them out on an ABI Prism Model 377. The sequences were analyzed further and aligned on Sequencer 3.1. (GeneCodes). Polymorphic variation in the VEGFR3 gene was identified by resequencing of a minimum of 50 chromosomes and allele frequencies were estimated from the sequence results. Recently, a genomic region of chromosome 5 containing the VEGFR3 gene region in unordered fragments was published (AC022095), and a direct sequence comparison confirmed our results.
Cell culture and transfection assays
To analyze the function and activity of the Vegfr3 promoter, luciferase reporter gene constructs were used in transfection assays of cultured cells. A 3 kb KpnI/NotI genomic fragment of the mouse genomic clone comprising the putative Vegfr3 promoter was cloned into the pGL3 basic reporter vector. pGL3 basic and pGL3 control vectors contained the firefly (Photinus pyralis) luciferase gene without promoter and driven by the SV40 promoter/enhancer, respectively. A restriction enzyme map of the mouse 3 kb Vegfr3 genomic fragment was made, deletions were introduced into the promoter fragment with the restriction enzymes indicated, and DNA fragments were inserted into the pGL3 basic vector. All constructs were confirmed by sequencing.
Mouse lung (LE-II) and brain endothelial cells (BEND) were grown in minimal essential medium and NIH3T3 murine fibroblasts in Dulbecco's modified minimum essential medium (DMEM) containing 10% fetal calf serum and antibiotics. Mouse keratinocytes (MK-2) were grown in low (2 mM) CaCl 2 DMEM containing 10% fetal calf serum, antibiotics, and epidermal growth factor (4 ng/ml). Cells were transfected using the calcium phosphate method. The minimal amount of plasmid registering full transcriptional activity was titrated prior to the experiments. In subsequent cases, 5 g of the appropriate reporter construct was transfected along with 0.2 g of pRL-TK (Promega) to control the variability in transfection efficiency. The pRL-TK vector contains the Herpes simplex virus thymidine kinase promoter region upstream of the Renilla reniformis luciferase gene. Cell extracts were prepared 48 h after transfection in passive lysis buffer (Promega). Luciferase activity was measured using Digene DCR-1 luminometer and Promega Dual Luciferase Assay System. The ratio of firefly luciferase activity to renilla luciferase activity in each sample served as a measure of the normalized luciferase activity, which was divided by the activity of the pGL3 control vector and expressed as relative luciferase activity. Each construct was transfected at least five times and data for each construct are presented as the mean Ϯ se. Relative luciferase activities among constructs were compared by a factorial analysis of variance, followed by Student's t test. Statistical significance was accepted at P Ͻ0.05.
Production and analysis of Vegfr3 promoter-LacZ embryos
A HindIII fragment of mouse Vegfr3 genomic sequence was cloned to the HindIII site of pSDKLacZpA. Transgenes containing either 3.6 kb HindIII/NotI, 1.6 kb BsaI/NotI, or 0.8 kb SpeI/NotI fragment of Vegfr3 genomic sequence, followed by the ␤-galactosidase gene and SV40pA, were excised from the plasmid by digestion with SalI, ApaI, and BsaI/SpeI, respectively. Transgenic DNA fragments were microinjected into fertilized oocytes of the FVB/N strain of mice and the injected zygotes were transplanted into oviducts of pseudopregnant C57BL/6xDBA/2J hybrid mice. Embryos were dissected from the decidua on day E15.5 and stained for ␤-galactosidase expression as described previously (29) . The embryos were genotyped by PCR analysis of the amnion DNA using primers 5Ј-TCTGTCGATCCTT-3Ј and 5Ј-GCTGGAT-GCGGCGTGCGGT-3Ј specific for the LacZ gene.
RESULTS
Organization and sequence variation of the human VEGFR3 gene
We recently found mutations in the VEGFR3 gene in hereditary lymphedema (41, 42) . Because VEGFR3 is one of a handful of receptor tyrosine kinase genes involved in human hereditary disease, we wanted to characterize this gene and its sequence variation. A cosmid clone containing the human VEGFR3 genomic sequences was analyzed by Southern blotting and hybridization with subcloned VEGFR3 cDNA fragments as probes, and suitable EcoRI fragments were subcloned into plasmid vectors. To characterize the exon-intron boundaries, these subclones were sequenced with primers based on the published human VEGFR3 cDNA sequence (40) . The VEGFR3 gene was found to consist of 31 exons (Fig. 1A) , the largest of which (exon 13) is only 363 bp in length ( Table 1 ). The 3Ј exons 30a and 30b are alternatively spliced into the mRNA, producing polypeptide isoforms differing by 65 amino acid residues (43) . The nucleotide sequences of VEGFR3 exonintron junctions were determined in their entirety; the lengths of most of the introns were estimated by using genomic PCR and further confirmed by comparing the lengths of the PCR products to the genomic sequence covering most of the VEGFR3 gene (Table 1 ). All exon-intron boundaries were found to conform to the 5Ј-GT-AG-3Ј splice site rule. The first intron of the VEGFR3 was only partially sequenced. Its length is at least 13.5 kb whereas the rest of the coding region from the second exon to in exon 30b spans more than 29 kb of genomic DNA.
The overall genomic organization of the VEGFR3 gene is highly similar to the previously published organization of the Vegfr1 and VEGFR2 genes (44, 45) . The coding capacity of the different exons is indicated in Fig. 1A in relation to the domain structure of the mature VEGFR-3 receptor protein, which is presented in Fig. 1B . Resequencing of VEGFR3 in a minimum of 25 individuals identified 22 intragenic single nucleotide polymorphisms (SNPs) and an intronic (CA) n repeat element. Six SNPs occurred in exons, two synonymous substitutions (G507T and T3198C), and four predicted to cause amino acid substitutions in the coding sequence (N149D, T494A, P641S, and R1146H). The intragenic polymorphic sites and allele frequency estimates are indicated in Table 2 .
Mouse and human VEGFR3 promoters contain two distinct regions of homology
Sequences upstream of the mouse Vegfr3 gene were cloned from a mouse genomic DNA library. Sequencing of clone F2N2.7, encompassing a 2.7 kb fragment upstream of the NotI site in the 5Ј leader sequence of the first coding exon, revealed that its 5Ј-end contains ϳ1.3 kb of repetitive sequences, followed by 1.4 kb of sequences not homologous to known genes (Fig. 1C ) . These sequences had two distinct regions of nonrepetitive sequence homology to the human promoter region that were separated by an Alu-like element in the human clone. These conserved regions, called homology regions 1 and 2 (HR1 and HR2 in Fig. 1C) , showed ϳ70% identity between the mouse and human sequences. HR1 contained conserved putative transcription factor binding sites, including a putative site for myocyte enhancer factor 2 (MEF-2) and several possible binding motifs for transcription factors for members of the Ets family, marked PEA3 and E1A-F (Fig.  1C) . HR2 was immediately upstream of the NotI site and contained multiple conserved binding sites for Sp1 like factors, as well as sequences that resemble the transcription start sites found in genes which do not contain a TATA box ( Fig. 1C; 46) . A) The genomic structure of human VEGFR3 consists of 31 exons (black boxes) of which 30a and 30b are alternatively spliced. The VEGFR3 exons encode seven Ig-homology domains (I-VII), a transmembrane region (TM), and tyrosine kinase domains (TK I and TK II), which are interrupted by the kinase insert sequence. B) Schematic structure of the VEGFR-3 receptor protein. C) Schematic structure of the upstream regions of the mouse and human VEGFR3 genes. Repetitive sequences are marked with green boxes, homology regions 1 and 2 (HR1 and HR2) as orange and blue boxes, respectively. In the human promoter, these elements are separated by an Alu repeat. The sequences of HR1 and HR2 with conserved putative transcription factor binding sites are shown in the figure.
Analysis of the mouse Vegfr3 promoter activity in cultured cells
To analyze whether the genomic sequences 5Ј of the VEGFR3 open reading frame confer endothelial cellspecific promoter activity, a 3 kb KpnI-NotI fragment upstream of the first coding exon of the mouse Vegfr3 gene was cloned into a luciferase reporter vector and transfected into cultured endothelial and nonendothelial cells. Cell extracts were assayed for luciferase activity (Fig. 2) . As the lymphatic vessels originate from the vascular endothelium and no lymphatic endothelial cell lines are currently available, blood vascular endothelial cells were used to study the Vegfr3 promoter activity and cell type specificity in vitro. The Vegfr3 expression in the endothelial cell lines used in the study was checked by Northern blot analysis. Mouse endothelial cells isolated from the lung (LE-II) did not express Vegfr3 whereas the brain endothelial cells did (data not shown). In LE-II and BEND cells, the 3 kb Vegfr3 promoter fragment showed 13% and 27% of the activity, respectively, of the SV40 promoter/enhancer used as a positive control. In NIH3T3 fibroblasts and MK-2 epithelial cells, the promoter showed much weaker activity (3% and 2%, respectively), indicating specificity for endothelial cells. However, the transcriptional activity of the 3 kb Vegfr3 promoter fragment in endothelial cells was weaker than the activity of a 1.1 kb HindIII-NcoI Tie promoter fragment (47).
Progressive 5Ј-deletions were made to the Vegfr3 promoter to characterize sequences critical for the promoter activity. Figure 2 shows schematically the deleted Vegfr3 promoter fragments used in the transfection experiments. As only background promoter activity was detected in NIH3T3 and MK-2 cells, no conclusions about the effects of mutations to Vegfr3 promoter activity were made based on the results obtained from these cell lines. The deletion of upstream sequences leaving only a 1.6 kb Vegfr3 promoter fragment increased significantly (57%) the promoter activity in BEND cells, whereas in LE-II cells, the promoter activity was slightly reduced (Fig. 2) . Further deletions leaving only 858 or 819 bp of the sequences upstream of the NotI site further increased the promoter activity in both LE-II and BEND cells. However, upon further deletion, luciferase activity driven by the 453 bp fragment was reduced by 40% in LE-II cells and 50% in BEND cells. These results suggest that the KpnI-ArvII Vegfr3 promoter fragment upstream of the HR1 contains DNA sequences inhibitory for transcription whereas the HR1 itself contains transcriptional enhancer elements.
Activity of the Vegfr3 regulatory sequences in transgenic mouse embryos
To analyze whether the Vegfr3 regulatory region identified in vitro is functional and specific to lymphatic as opposed to blood vascular endothelium in vivo, we generated transgenic mouse embryos having the 3.6 kb HindIII-NotI promoter fragment upstream of the LacZ reporter gene. The embryos were stained and analyzed for ␤-galactosidase expression at E15.5. At this developmental stage, the lymphatic vessels are developing, while the skin is still permeable to the ␤-galactosidase staining reagents. Of 11 embryos positive for the 3.6 kb Vegfr3 promoter/LacZ DNA, endothelial-specific transgene expression was observed in only one (Fig. 3A) . Three other embryos with staining in a subset of endothelial cells also showed some ectopic expression. Two DNA-positive embryos showed only ectopic staining and five did not stain at all. As the 3.6 kb Vegfr3 promoter fragment could occasionally target expression of the LacZ reporter gene to the endothelium of mouse embryos, we tested whether the 1.6 kb BsaI-NotI promoter fragment could drive the reporter gene ex- pression specifically to the lymphatic endothelium. Based on whole mount analysis, of the 22 embryos positive for the 1.6 kb Vegfr3 promoter/LacZ transgene DNA endothelial-specific transgene expression was observed in two, while seven embryos had transgene expression also in nonendothelial cells. One of the two embryos having endothelial cell-specific expression is shown in Fig. 3B . As can be seen from the Fig. 3A , B, the ␤-galactosidase marker was expressed in a loose branching network pattern in the skin in both cases. This pattern was particularly evident in the dorsal parts of the developing forelimbs and in the neck region. The morphology of these structures suggested that they represent developing lymphatic vessels that form in the skin at this stage of mouse development by an (lymph)angiogenic mechanism. A similar kind of staining pattern, although much stronger and more extensive, was seen in the Vegfr3 LacZ knock-in embryos (Fig.  3C ) . No blue staining could be found in similarly treated transgene-negative embryos. The vascular specificity of the staining patterns was confirmed by analyzing tissue sections. Skin sections of the 3.6 kb Vegfr3 promoter/LacZ transgenic embryo revealed that although the ␤-galactosidase staining was very faint, it was clearly restricted to the developing lymphatic endothelium (Fig. 3D) . Analysis of the sections from the 1.6 kb Vegfr3 promoter/LacZ transgenic embryos confirmed that this fragment was sufficient to drive ␤-galactosidase expression largely to the lymphatic vessels (Fig. 3E) , although some veins were also weakly positive. However, the other transgenic embryo for the 1.6 kb Vegfr3/LacZ construct, which showed staining only in the lymphatics, had some weak staining in the chondrocytes. Analysis of tissue sections of the Vegfr3/LacZ knock-in embryo confirmed the endogenous pattern of expression and weaker activity of the promoter fragments (Fig. 3F) . Staining of blood capillaries or arteries was not observed in either case.
As the 1.6 kb promoter fragment was able to drive the gene expression to the lymphatic endothelium in some of the embryos, we continued to study the reporter gene expression targeted by the 0.8 kb SpeI-NotI Vegfr3 promoter fragment, which showed stronger promoter activity in cultured cells. In the transgenic analysis of the 0.8 kb Vegfr3 promoter/LacZ construct, 20 embryos screened were transgene positive; of these, four embryos had staining in endothelial cells. Three also had ectopic staining in other cell types. However, even in the embryos showing endothelial cell-specific expression of the transgene, the staining pattern was not restricted to the developing lymphatic endothelium. Strong promoter activity was found also in the developing capillary-sized vessels, e.g., in the head (data not shown). Table 3 summarizes the results from the Vegfr3 promoter/LacZ transgenic studies.
DISCUSSION
In this study, we have characterized the structure of the human VEGFR3 gene and both mouse and human VEGFR3 promoters. The coding sequence of the VEGFR3 gene is organized into 31 exons that closely correspond to the genomic organization of the mouse Vegfr1 and human VEGFR2 genes (44, 45) . In our analyses, we also identified many polymorphisms of the VEGFR3 sequence. The data concerning the exonintron boundaries and polymorphisms is important and useful from the clinical point of view as we have recently demonstrated that VEGFR3 missense mutations are a cause of familial early onset lymphedema (41, 42) . Due to the complexity and heterogeneity of this disease, it is likely that several other VEGFR3 mutations may also be found in different lymphedema families. Using the information about the VEGFR3 genomic structure, intragenic polymorphisms and linkage studies in families with lymphedema or other inherited abnormalities of the lymphatic system should allow rapid screening for mutations in VEGFR3-linked families. Since the endothelial cell-associated genes are candidate loci for vascular dysmorphogenesis syndromes and hereditary angiogenic disorders, analysis of VEGFR3 mutations from patients suffering from lymphatic disorders might reveal the molecular basis of such phenotypes.
We have also isolated and partially characterized the genomic regions upstream of the mouse and human VEGFR3 genes. The upstream sequences showed ϳ70% identity in two distinct regions, which represented the putative 5Ј enhancer/promoter and 3Ј minimal promoter elements, respectively. No classical TATA or CAAT boxes were found in VEGFR3. The 3 kb fragment of the 5Ј-flanking sequence of the mouse Vegfr3 demonstrated activity in cultured endothelial cells but only minimal activity in keratinocytes and fibroblasts. Deletion studies of the Vegfr3 promoter indicated that both homology elements were needed for activity. The 5Ј homology element had conserved putative binding sites for transcription factors conforming to the MEF-2, NF-1, AP-2, GATA, and Ets families. Two Ets family transcription factor binding sites, PEA3 and E1A-F, were conserved in the mouse and human VEGFR3 promoters. Sites for Ets-related transcription factors are also found in all other known promoters showing endothelial specificity in vivo, such as in the promoters of genes encoding Tie-1, Tie-2, VE-cadherin, ICAM-2, and vWF (29 -31, 33, 35-37) . The 3Ј homology region contains multiple conserved binding sites for Sp1 like factors as well as sequences that resemble the transcription start sites found in genes that do not contain a TATA box. The transcription factors controlling the VEGFR3 gene expression remain unknown and further studies are needed to determine which consensus binding sites are critical for the VEGFR3 promoter activity.
We also studied the ability of three Vegfr3 promoter fragments to target gene expression in the developing lymphatic endothelium in vivo. Our results from transgenic embryos at E15.5 indicate that the 3.6 kb and 1.6 kb Vegfr3 promoter fragments contained specific elements sufficient to direct gene expression to the lymphatic endothelium. However, as only few of the transgenics showed a similar staining pattern to that of the Vegfr3/LacZ knock-in embryos, the gene expression driven by these promoter fragments is apparently very sensitive to interference by the transgene integration site and further enhancer elements needed for reproducible endothelium-specific reporter gene expression are likely to be missing from these promoter fragments. Many tissue-specific gene regulatory elements are located within the first two introns, although such elements occasionally can be found at a great distance, even in the 3Ј parts of genes. Vegfr2 and Tie2 are examples of endothelial cell-specific genes whose activity is partly regulated by enhancers located in their first introns (31, 32) . Therefore, we are currently analyzing the large first introns of the mouse and human Vegfr3 genes to locate putative enhancer elements. We have sequenced the first intron of the mouse Vegfr3 consisting of 15 kb of genomic DNA. When compared with the human VEGFR3 first intron, which has recently become available in the GenBank, the sequences were found to be ϳ70% homologous. Several short regions showing high homology were found, but so far no additional enhancers could be identified in transfection studies using various DNA fragments from the mouse intron (unpublished data of the authors).
Lymphatic vessels are quite different from arteriae, veins, and capillaries in structure. The lymphatics are characterized by an extremely permeable, thin endothelial lining devoid of a basal lamina. In addition, the small lymphatic vessels typically lack supporting cells, such as pericytes or smooth muscle cells (21, 48) . These differences indicate that the lymphatic endothelial cells represent a differentiated form of endothelial cells. Differentiation of endothelia to arterial, venous, and lymphatic lineages has not been understood at a molecular level. Recent evidence suggests that arteries and veins are genetically determined at the earliest stages of vasculogenesis (49, 50) . It is unclear at precisely what stage lymphatic vessels are determined. One possibility is that VEGF-C and VEGF-D expressed by smooth muscle cells of arteries and veins would be involved in directing the formation of lymphatic vessels around them (38) . The isolation of the VEGFR3 promoter now makes it possible to identify the transcription factors that contribute to lymphatic development using techniques of mouse molecular genetics. The relevant transcription factor binding sites in addition to the e NO: number of embryos with no staining.
f Weak staining was observed in a subset in chondrocytes in one of the embryos.
coding sequence may also be targets of mutations in human lymphedema.
Previous studies have aimed to identify promoter elements necessary for uniform vascular endothelial cell-specific gene expression. However, a major obstacle in gene therapy directed to endothelial cells is the fact that leakage of catheters and blood flow rapidly washes away delivery vehicles, resulting in undesired gene expression in distant organs, particularly in the liver (51) . Therefore, promoters that restrict expression of transgenes to particular subsets of endothelial cells may be more desirable in such settings. In hereditary lymphedema with reduced VEGFR3 signaling in heterozygous affected individuals (41, 42) , genes that would induce VEGFR-3 signaling specifically in the lymphatic endothelium might improve the growth and function of lymphatic vessels without side effects in other tissues. Another potential use for the Vegfr3 promoter would be in 'partial' rescue experiments, as null mutations in several endothelial-specific genes of mice are known to lead to embryonic lethality at an early stage. Although the transcriptional activity of the Vegfr3 promoter is relatively weak, identification of additional endogenous enhancers or the use of enhancers increasing promoter activity without losing its cellular specificity might increase the efficacy of Vegfr3 promoter in the potential applications described above (52) .
